Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
With high relapse and overdose rates across substances, novel therapeutic strategies are urgently needed
What the clinical data has reported: Phase 2 trials of Retatrutide (Jastreboff et al., NEJM 2023, and follow-ups) reported: - Dose-dependent body weight reduction across 24- and 48-week dosing intervals - Reductions in liver fat content measured by MRI-proton density fat fraction (MRI-PDFF) in populations with metabolic dysfunction-associated steatotic liver disease (MASLD) - Glycaemic marker improvement (HbA1c, fasting glucose) in type 2 diabetes cohorts - Dose-related gastrointestinal adverse effects consistent with the GLP-1/GIP class nausea, vomiting, diarrhoea Important: these are clinical trial findings in regulated patient populations
So, it keeps overall health during caloric restriction
However, this has not been studied long-term with either of these peptide versions, which is why it is important to only use peptides under the care of a professional who can monitor you for unwanted side effects
Second, storage instructions
US$ 26.63
US$ 29.72
US$ 28.52
US$ 27.33
US$ 22.35
US$ 24.50
US$ 24.76
